Evidence map›Paper›PMID 39490481›Full record

ArticleInternational journal of biological macromolecules2024

Clofazimine inhibits small-cell lung cancer progression by modulating the kynurenine/aryl hydrocarbon receptor axis.

Gunjan Sharma, K M Abdullah, Faizan Abul Qais, Parvez Khan, Jesse L Cox, Tarique Sarwar, Mohd Wasim Nasser, Surinder K Batra, Jawed A Siddiqui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological macromolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gunjan SharmaDepartment of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson MS-39216, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE-68198, USA; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson MS-39216, USA.
K M AbdullahDepartment of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson MS-39216, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE-68198, USA; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson MS-39216, USA.
Faizan Abul QaisDepartment of Agricultural Microbiology, Faculty of Agricultural Sciences, Aligarh Muslim University, Aligarh, UP 202002, India.
Parvez KhanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE-68198, USA.
Jesse L CoxDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha NE-68198, USA.
Tarique SarwarDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
Mohd Wasim NasserDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE-68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE-68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Jawed A SiddiquiDepartment of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson MS-39216, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE-68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson MS-39216, USA. Electronic address: jsiddiqui@umc.edu.

Funding

Novel approach to attenuate small cell lung cancer growth and metastasisR01CA218545 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2018 to 2022
$2.6M
Targeting MUC5AC mucin in breast cancer brain metastasisR01CA241752 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2021 to 2025
$2.3M
NCI NIH HHS R01 CA218545NCI NIH HHS R01 CA241752
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is one of the highly metastatic malignancies that contributes to ∼15 % of all lung cancers. Most SCLC patients (50-60 %) develop osteolytic bone metastases, significantly affecting their quality of life. Among several factors, environmental pollutant 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) and kynurenine (Kyn), an endogenous ligand derived from tryptophan (Trp) metabolism, activate the aryl hydrocarbon receptor (AhR) and are responsible for SCLC progression and metastasis. Further, elevated AhR expression in bone cells intensifies bone resorption, making the Kyn/AhR axis a potential target for the bone metastatic propensity of SCLC. We first assessed the expression profile of AhR in human SCLC cell lines and found a significantly increased expression compared to normal lung cells. Additionally, we also evaluated the clinical significance of AhR expression in the patient samples of SCLC along with the relevance of the same in the Rb1

Indexed as

ClofazimineKynurenineLung NeoplasmsReceptors, Aryl HydrocarbonSmall Cell Lung CarcinomaAnimalsCell Line, TumorCell ProliferationDisease ProgressionHumansMiceSignal TransductionClofazimineKynurenineReceptors, Aryl HydrocarbonAryl hydrocarbon receptorBone metastasisClofazimineKynureninSmall cell lung cancer

Identifiers

PMID39490481
PMCPMC12060262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.